- Regenerative medicine company Orthocell (OCC) secures patents in Canada and Hong Kong for CelGro
- The patents cover the method of using CelGro to repair a defect in soft tissues, such as tendons, ligaments and nerves, avoiding the use of damaging sutures
- This announcement follows the patents already approved in Australia, New Zealand, China and Japan, with further application progress in US and EU
- On the market this morning, Orthocell is up 3.19 per cent and trading at 48.5 cents per share
Orthocell (OCC) has been granted patents in Canada and Hong Kong for its novel CelGro collagen medical device platform for soft tissue regeneration applications.
The patents titled “suture-less repair of soft tissue” are now approved in Australia, New Zealand, China, Japan, Hong Kong, and Canada, with further applications progressing in US and EU. The patents will expire on October 12, 2035.
Pre-clinical and clinical results show suture-less repair of soft tissue has potential to greatly improve the efficiency and efficacy of surgical procedures.
Repairing damaged peripheral nerves often involves reconstructive surgery and the use of stitches to reconnect the nerve ends.
Orthocell’s CelGro has shown to produce superior nerve repair and return of muscle function in severed peripheral nerves when compared to the traditional repair method.
Managing Director Paul Anderson said the patents are an important addition to the company’s global portfolio.
“Suture-less or tensionless repair is of particular importance in the optimal repair of damaged nerves and is a key part of the repair process undertaken in the CelGro nerve regeneration clinical study,” he said.
“This comes at a perfect time for the company as we move our exciting pipeline products in nerve, tendon and ligament repair through the registration process
in the US, EU and AUS.”
On the market this morning, Orthocell was up 3.19 per cent and trading at 48.5 cents per share at 10:25 am AEST.